Evidence map›Paper›PMID 35844964›Full record

ArticleBiosafety and health2022

Harmonizing the COVID-19 sample biobanks: Barriers and opportunities for standards, best practices and networks.

Balwir Matharoo-Ball, Mbayame Diop, Zisis Kozlakidis

Expression of concernAbstract read
In one paragraph

Article in Biosafety and health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Balwir Matharoo-BallDirector of Biobank, G42 Healthcare, Abu Dhabi, United Arab Emirates.
Mbayame DiopUniversité Cote d'Azur, Nice 06100, France.
Zisis KozlakidisInternational Agency for Research on Cancer, World Health Organization, 69372 Lyon CEDEX 08, France.

Funding

World Health Organization 001
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the practice of infectious diseases biobanking, as well as existing challenges and opportunities. Thus, the future of infectious diseases biobanking in the post-pandemic era, shall not be an "entry-level version" of its counterpart in non-communicable diseases and large population cohorts, but incorporate the lessons learned. Biobanks constitute a critical research infrastructure supported by harmonized practices through the implementation of international standards, and perceived within the broader scope of healthcare's intersection with research. This perspective paper considers the barriers in biobanking and standardization of practices, as well as the emerging opportunities in the field.

Indexed as

Biobank best practicesBiobank networksBiobanksBiobank standardsCOVID-19

Identifiers

PMID35844964
PMCPMC9270233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.